Ayahuasca and debut of psychosis, description of a clinical case
E. E. Morales Castellano, P. Rivero Rodríguez, Marina Martínez Grimal, J. J. Tascón Cervera, A. M. Morales Rivero
European Psychiatry April 1, 2025 DOI: 10.1192/j.eurpsy.2025.1620 via OpenAlex
Summary
AI-generated from the abstractAyahuasca, a hallucinogenic brew used traditionally in Amazonian ceremonies, can trigger psychotic episodes in people with a history of psychiatric disorders. This case report describes a patient who developed a psychosis requiring hospitalization after consuming ayahuasca, with symptoms including hallucinations and delusions. Treatment with antipsychotics led to complete symptom resolution. The authors emphasize that hallucinogens may interact negatively with antipsychotic medications, reducing treatment effectiveness or causing adverse effects. Given ayahuasca's increasing use in developed societies, the report highlights the need for regulation, research, and psychoeducation about its potential risks, especially for vulnerable individuals.
Study at a glance
| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A patient who consumed ayahuasca and presented a psychotic episode |
| Intervention | antipsychotics |
| Key finding | Ayahuasca use can trigger psychotic episodes in individuals with a history of psychiatric disorders, but symptoms may resolve completely with antipsychotic treatment. |
Abstract
Introduction The relationship between psychosis and ayahuasca use is a topic of considerable interest and debate in the scientific and medical community. Ayahuasca is traditionally used in shamanic ceremonies in the Amazon, composed mainly of the Banisteriopsis caapi vine and the leaves of Psychotria viridis, which contain DMT (dimethyltryptamine), a powerful hallucinogen. Ayahuasca induces altered states of consciousness, with experiences that can include visions, deep introspection, and changes in the perception of reality. The experience can be intense and emotionally overwhelming. In individuals with a history of psychosis or psychiatric disorders, ayahuasca may more easily trigger a psychotic episode. The interaction with neurotransmitters and the serotonergic system can influence their appearance. We report a case of a patient who, after consuming ayahuasca, presented a psychotic episode that required hospitalization. After the initiation of treatment with antipsychotics, the condition had a favorable evolution towards the complete resolution of the symptoms. Given the increasingly frequent use of ayahuasca in developed societies, the current case highlights the needs to understand, regulate and research the use of ayahuasca. Additionally, raising awareness of the potential risks of ayahuasca use through psychoeducation should be implemented. Objectives Describe the case of a psychotic episode induced by ayahuasca: Clinical debut, symptoms and evolution after initiation of treatment. Methods Description of a clinical case as well as bibliographic review. Results The relationship between hallucinogens and psychosis is a critical area of study due to the intense and potentially destabilizing effects that hallucinogens can have on people with this condition. Hallucinogens can trigger or aggravate psychotic symptoms, which may include hallucinations and delusions. We must keep in mind that hallucinogens can interact negatively with antipsychotics or other medications used to treat psychosis. These interactions may reduce the effectiveness of treatment or cause adverse side effects, as well as affect adherence to treatment, as it may lead to an alteration in the perception of the need for medication or the ability to follow the treatment regimen. Conclusions Ayahuasca use can have profound and potentially destabilizing effects, especially in people with a history of psychotic disorders. Although there is therapeutic potential, it is crucial to proceed with caution and under the supervision of trained professionals. Proper preparation and risk assessment are essential to minimize potential adverse effects. Disclosure of Interest None Declared